Status:
COMPLETED
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
Lead Sponsor:
NodThera Limited
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Participants...
Detailed Description
The goal of this clinical trial is to evaluate the effects of NT-0796 on inflammation in obese participants at risk of cardiovascular disease, evaluate the effects of NT-0796 on body weight and compos...
Eligibility Criteria
Inclusion
- Male or female aged 18 years or older.
- Body mass index (BMI) ≥30 and ≤40 kg/m2 at screening.
- Presence of 1 or more of the following risk factors for atherosclerotic cardiovascular disease:
- History of controlled hypertension
- History of hypercholesterolemia
- History of high-density lipoprotein levels
- Controlled Type 1 or Type 2 Diabetes mellitus
Exclusion
- History of stroke with residual neurological deficit within 2 years or transient ischemic attack within 6 months
- History of acute coronary syndrome (ACS)
- Stable angina.
- Diagnosis of congestive heart failure
- Evidence of past or current infection with Hepatitis B or Hepatitis C
Key Trial Info
Start Date :
October 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2024
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT06129409
Start Date
October 10 2023
End Date
April 15 2024
Last Update
December 16 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Miami, Florida, United States, 33147
2
Investigative Site
Austin, Texas, United States, 78744